Breast Cancer

Faculty

Charles E Geyer Jr

MD

UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Professor of Medicine, Division Chief, Malignant Hematology and Medical Oncology

NSABP Foundation, Pittsburgh, Pennsylvania

Chief Scientific Officer

NRG Oncology, Philadelphia, Pennsylvania

Associate Group Chair

Faculty

Maryam Lustberg

MD, MPH

Yale School of Medicine, New Haven, Connecticut

Professor of Internal Medicine (Medical Oncology), Director, Center for Breast Cancer, Chief, Breast Medical Oncology

Faculty

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

Faculty

Seth Wander

MD, PhD

Massachusetts General Hospital, Boston, Massachusetts

Director of Precision Medicine, Termeer Center for Targeted Therapies, Director of Translational Research, Breast Oncology Program

Harvard Medical School, Boston, Massachusetts

Assistant Professor of Medicine

Prostate Cancer

Faculty

Neeraj Agarwal

MD, FASCO

The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Faculty Medical Oncologist, Dana-Farber Cancer Institute, Co-Director, Prostate Cancer Program, Harvard Cancer Consortium

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Relapsed/Refractory Multiple Myeloma

Faculty

Sagar Lonial

MD, FACP, FASCO

Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Chair and Professor, Department of Hematology and Medical Oncology, Anne and Bernard Gray Family Chair in Cancer, Chief Medical Officer

Faculty

Paul G Richardson

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

Harvard Medical School, Boston, Massachusetts

RJ Corman Professor of Medicine

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

Join us on Saturday, October 17^th from 7:15 AM to 12:00 PM eastern time.

7:15 AM – 7:25 AM – Welcome, Introductions and Meeting Overview

7:25 AM – 9:40 AM – MODULE 1: Breast Cancer
Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease
Relapsed/Refractory (R/R) HR-Positive Metastatic Breast Cancer
HER2-Positive Breast Cancer
Triple-Negative Breast Cancer

9:40 AM – 10:00 AM – BREAK

10:00 AM – 11:00 AM – MODULE 2: Prostate Cancer
Hormonal Therapy for Prostate Cancer
Other Therapeutic Strategies for Prostate Cancer

11:00 AM – 12:00 PM – MODULE 3: Relapsed/Refractory (R/R) Multiple Myeloma
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for R/R MM
Antibody-Drug Conjugates and Other Strategies for R/R MM

12:00 PM – Meeting Adjourns

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

Breast Cancer

• Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic breast cancer.
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for hormone receptor (HR)-positive localized or metastatic breast cancer in order to appropriately counsel patients regarding the optimal clinical use of these agents.
• Recognize the biological rationale for the development of agents targeting the PI3K/AKT/mTOR pathway, and recognize available data with FDA-approved treatments for patients with HR-positive metastatic breast cancer (mBC) with and without PIK3CA/AKT1/PTEN alterations.
• Understand the mechanism of action of, published research findings with and current and future clinical role of oral selective estrogen receptor degraders (SERDs) alone and in combination with other agents and of PROTAC (PROteolysis TArgeting Chimera) ER degraders for patients with HR-positive mBC harboring ESR1 mutations.
• Analyze the scientific justification for, available data with and potential clinical role of oral SERDs as adjuvant treatment for localized HR-positive, HER2-negative breast cancer.
• Evaluate published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for HER2-positive localized and metastatic breast cancer.
• Review published research data supporting the use of chemotherapy or antibody-drug conjugate (ADC) therapy in combination with anti-PD-1/PD-L1 antibodies for localized or metastatic triple-negative breast cancer, and use this information to make appropriate treatment recommendations.
• Interrogate published Phase III research findings documenting the efficacy of TROP2-directed ADC monotherapy for mBC to determine the current clinical applicability of this approach.
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

Prostate Cancer

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients considering the potential benefits and risks of new and established forms of hormonal therapy.
• Evaluate the biological rationale for and available data with perioperative androgen deprivation therapy in combination with an androgen receptor (AR) pathway inhibitor for high-risk localized or locally advanced prostate cancer, and review the potential clinical role of this novel strategy.
• Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
• Assess the available research database supporting the use of PARP inhibitors in combination with AR pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Evaluate available data with novel AKT inhibitors in combination with hormonal therapy for mHSPC with PTEN deficiency, and identify patients who may be appropriate for this form of treatment.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for R/R MM.
• Develop an understanding of the current clinical research database with various chimeric antigen receptor T-cell therapy platforms in the management of R/R MM in order to optimally integrate this novel therapeutic strategy into current treatment algorithms.
• Assess available research data with B-cell maturation antigen (BCMA) and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms.
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed ADC therapy for R/R MM, and identify patients appropriate for treatment with these agents.
• Analyze the mechanism of action of, published efficacy and safety findings with and the current and future clinical role of cereblon E3 ligase modulators in the management of R/R MM.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM.
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 4.25 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Number of Contact Hours Awarded
This educational activity for 4.25 contact hours is provided by Research To Practice.

This activity is awarded 4.25 ANCC pharmacotherapeutic contact hours.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/FCSSummit2026/Oct17/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.0425 CEU (4.25 contact hours) of continuing education credit. To receive 4.25 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committees: Abeona Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus, Vir Biotechnology Inc; Consulting Agreements: Acerand Therapeutics, Blue Earth Diagnostics, Boundless Bio, Clarivate, Clearview Healthcare Partners, Curium, DAVA Oncology, EcoR1 Capital LLC, Global Life Sciences Alliance, Health Monitor Network, Johnson & Johnson, Lilly, Lumanity, Propella Therapeutics Inc, Slingshot Insights, Third Bridge, Z-Alpha; Contracted Research: Actinium Pharmaceuticals Inc, MacroGenics Inc, Merck, MorphoSys, Novartis, Orion Corporation, pharmaand GmbH, Seagen; Patents: Qiagen; Nonrelevant Financial Relationships: Binaytara Foundation, Conexiant, eCancer, Fred Hutch Cancer Center, MJH Life Sciences, Targeted Oncology, The Medical Educator Consortium. Dr Geyer — Contracted Research: Abbott, Artera, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group. Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc. Dr Lustberg — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Sandoz Inc, a Novartis Division; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP. Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics. Dr Richardson — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Karyopharm Therapeutics, Oncopeptides. Dr Wander — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Genentech, a member of the Roche Group, Lilly, Menarini Group, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc; Consulting Agreements: 2nd.MD, Arvinas, Biovica International AB, Boundless Bio, Daiichi Sankyo Inc, Delcath Systems Inc, Foundation Medicine, Gilead Sciences Inc, Halda Therapeutics, Novartis, Pfizer Inc, Precede Biosciences, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Arvinas, Boundless Bio, Genentech, a member of the Roche Group, Halda Therapeutics, Lilly, Menarini Group, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc. 

MODERATOR
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Johnson & Johnson, Kite, A Gilead Company, Novartis, Puma Biotechnology Inc, Rigel Pharmaceuticals Inc, and Stemline Therapeutics Inc.

The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2400

Meeting Room
Tuscany Ballroom (Salons D-H) — Lobby Level

Hotel Room Reservations

• Florida Cancer Specialists (FCS) members, please be sure to book accommodations in the FCS room block.
• For all other registrants, room reservation information will be included with the confirmation email after you have registered for this program.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Thank you for your interest in our CME/MOC, ACPE and NCPD program. At this time online preregistration is closed for this event.

Our onsite registration desk will be open at 6:30 AM ET on Saturday, October 17^th. If you are interested in attending, please visit our registration desk in the foyer of the Tuscany Ballroom, Salons D-H, on the lobby level of The Ritz-Carlton Orlando, Grande Lakes hotel. Please note, seating is limited for this event, and we will do our best to accommodate onsite attendees on a first come, first served basis (clinicians in practice will be prioritized). Onsite registration does not guarantee participation in meal services.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

Faculty

Paolo F Caimi

MD

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

Professor of Medicine

Cleveland Clinic Cancer Center, Cleveland, Ohio

Associate BMT and CT Director for Cellular Therapy

Case Comprehensive Cancer Center, Cleveland, Ohio

Medical Director, Clinical Research Office

Faculty

Marc S Hoffmann

MD

University of Kansas Cancer Center, Kansas City, Kansas

Director, Lymphoma Program, Associate Professor, Division of Hematologic Malignancies and Cellular Therapeutics

Faculty

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Moderator

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Additional faculty to be announced.

Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Topics to Be Discussed

• Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates (ADCs) into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
• Clinical Utility of CD19-Directed Monoclonal Antibodies in the Management of DLBCL and Follicular Lymphoma (FL)
• Optimal Use of CD19-Directed ADCs for R/R DLBCL and FL
• Current and Future Role of Bruton Tyrosine Kinase Inhibition in the Management of Non-Hodgkin Lymphoma
• Potential Role of Bcl-2 Inhibitors in the Management of Mantle Cell Lymphoma

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.

Learning Objectives
At the conclusion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and use this information in patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in therapy for R/R DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for mantle cell lymphoma (MCL), FL and DLBCL, and determine the role of these agents in current and future clinical management.
• Assess the scientific basis for and available research findings with the use of Bcl-2 inhibitors for R/R MCL in order to prepare for the potential availability of this novel treatment strategy.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients..

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Caimi — Advisory Committees: AbbVie Inc, Autolus, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Novartis, Recordati; Consulting Agreements: Bristol Myers Squibb; Contracted Research: ADC Therapeutics, Genmab US Inc, Incyte Corporation, Iovance Biotherapeutics, Recordati; Data and Safety Monitoring Boards/Committees: ADC Therapeutics; Stock OPTIONS — Private Companies: Abcon Therapeutics. Dr Hoffmann — Advisory Committees: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Novartis; Consulting Agreements: AbbVie Inc; Data and Safety Monitoring Boards/ Committees: Novartis. Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Additional faculty to be announced.

MODERATOR
Dr Smith — Advisory Committees: Genentech, a member of the Roche Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group; Contracted Research: Ipsen Biopharmaceuticals Inc. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb and Incyte Corporation.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Topics to Be Discussed

• Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)
• Ocular Toxicities and Other Tolerability Considerations with ADCs for MM
• Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for MM to facilitate their integration into management algorithms.
• Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
• Implement a plan of care to recognize and manage the toxicities associated with bispecific antibodies and ADCs commonly used for MM in order to maintain patient quality of life and time on treatment.
• Assess available research data with BCMA-directed bispecific antibodies for patients with relapsed/refractory (R/R) MM, and appreciate the clinical role of these agents.
• Recall recently presented clinical trial results establishing the definitive efficacy of BCMA-directed bispecific antibody therapy in combination with anti-CD38 monoclonal antibody therapy for patients with R/R MM, and integrate this novel therapeutic strategy into management algorithms.
• Recall available data with novel bispecific antibody- and ADC-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma, Takeda Pharmaceutical Company Limited. Dr Trudel — Advisory Committees: AstraZeneca Pharmaceuticals LP, GSK, Janssen Biotech Inc, Kite, A Gilead Company, Opna Bio, Pfizer Inc, Sanofi; Consulting Agreements: GSK; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Pfizer Inc, Roche Laboratories Inc. Additional faculty to be announced.

MODERATOR
Dr Callander has no relevant financial relationships to disclose. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 3:15 PM to 5:15 PM central time (4:15 PM to 6:15 PM eastern time).

Topics to Be Discussed

• Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias
• Managing MF in Patients with Anemia
• Managing MF in Patients with Thrombocytopenia
• Novel Approaches for MF Potentially Nearing the Clinic
• Other Promising Novel Agents Under Investigation for MF

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
• Analyze how age, performance status and other biological and disease-related factors affect the decision to initiate therapy and the subsequent selection of treatment for patients with primary and secondary MF.
• Appraise available research informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with anemia, thrombocytopenia or compromised renal function, and personalize treatment recommendations based on this information.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Understand the biological rationale for the inhibition of exportin 1 (XPO1) in patients with MF, and reflect on available research findings with XPO1 inhibitors in combination with JAK inhibition as front-line treatment.
• Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, such as BET inhibitors and MDM2 inhibitors, and consider the potential role of these emerging approaches.
• Recognize the spectrum, frequency and severity of side effects associated with JAK inhibitors and other therapies employed in the treatment of MF, and implement a plan of care to recognize, prevent and manage resultant toxicities.
• Assess the mechanism of action of, available research findings with and ongoing investigation of other novel agents for MF, and consider the potential clinical application of these approaches.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Masarova — Advisory Committees: Cogent Biosciences, Karyopharm Therapeutics, PharmaEssentia. Dr Mesa — Consulting Agreements: Bristol Myers Squibb, Genentech, a member of the Roche Group, Geron Corporation, GSK, Incyte Corporation, Lilly, PharmaEssentia, Sobi, Takeda Pharmaceuticals USA Inc, Telios Pharma Inc; Contracted Research: Incyte Corporation, PharmaEssentia; Data and Safety Monitoring Boards/Committees: Geron Corporation, Kartos Therapeutics, Telios Pharma Inc. Dr Passamonti — Advisory Committees: AbbVie Inc, Bristol Myers Squibb, GSK, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma, Takeda Pharmaceutical Company Limited; Data and Safety Monitoring Boards/Committees: Menarini Group (myeloma study); Speakers Bureaus: AOP Orphan Pharmaceuticals GmbH, Bristol Myers Squibb, GSK, Incyte Corporation, Menarini Group, Novartis, Stemline Therapeutics Inc. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

MODERATOR
Dr Kuykendall — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Cogent Biosciences, CTI BioPharma, a Sobi Company, Deciphera Pharmaceuticals Inc, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Merck, Novartis, Ono Pharmaceutical Co Ltd, Opna Bio, PharmaEssentia, Protagonist Therapeutics Inc, Silence Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, GSK, Janssen Biotech Inc, Kartos Therapeutics, Novartis, Protagonist Therapeutics Inc. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, and Novartis.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Faculty

Toby A Eyre

MBChB, DipMedEd, MRCP, MD

Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Headington, Oxford, United Kingdom

Haematology Consultant, Honorary Senior Clinical Lecturer in Haematology

Faculty

Talha Munir

MBBS, MRCP, PhD

St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Consultant Hematologist

Faculty

Mazyar Shadman

MD, MPH

Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington

Professor, Innovators Network Endowed Chair, Deputy Chief Medical Officer, Medical Director, Cellular Immunotherapy, Professor, Clinical Research Division

Moderator

Shazia Nakhoda

MD

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Assistant Professor in the Department of Hematology/Oncology

Faculty

William G Wierda

MD, PhD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey, Section Chief, Chronic Lymphocytic Leukemia, Center Medical Director, Department of Leukemia, Division of Cancer Medicine, Deputy Division Head for Clinical and Educational Affairs

Additional faculty to be announced.

Join us on Friday, December 11^th from 7:30 AM to 9:30 AM central time (8:30 AM to 10:30 AM eastern time).

Topics to Be Discussed

• Front-Line Therapy for Patients with Chronic Lymphocytic Leukemia (CLL) without High-Risk Features 
• Initial Treatment for High-Risk CLL 
• Available Data with and Role of Noncovalent Bruton Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed CLL 
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL 
• Novel Agents in Clinical Development for CLL 

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients with newly diagnosed disease. 
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences. 
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents. 
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options. 
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL to effectively inform patients about the risks and benefits of this novel treatment strategy. 
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review available data with this strategy in patients with newly diagnosed and relapsed/refractory (R/R) CLL. 
• Appraise clinical investigator best practices for various R/R CLL management situations, and use this information to facilitate improved clinical decision-making. 
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL and, where applicable, discuss clinical trial participation with eligible patients. 

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — Dr Munir has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Eyre — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Autolus, BeOne, Bristol Myers Squibb, Galapagos NV, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Kite, A Gilead Company, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Roche Laboratories Inc. Dr Shadman — Advisory Committees and Consulting Agreements: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, MorphoSys, Nurix Therapeutics Inc, Pfizer Inc, Pierre Fabre; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Merck, MorphoSys, Nurix Therapeutics Inc, Sana Biotechnology; Stock OPTIONS — Private Companies: Koi Biotherapeutics Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb (spouse employment). Dr Wierda — Consulting/Advisory Boards, No Compensation: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Intellisphere, Johnson & Johnson, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Bristol Myers Squibb Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial and Nonfinancial Relationships: National Comprehensive Cancer Network (Chair, CLL), Supported by the NIH/NCI under award number P30 CA016672 and used MD Anderson Cancer Center Support Grant (CCSG) shared resources, Wiley China (consulting/advisory board, no compensation). Additional faculty to be announced.

MODERATOR
Dr Nakhoda — Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeOne, and Lilly.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

Topics to Be Discussed

• Current Use of BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma
• Tolerability Considerations with BCMA-Targeted CAR T-Cell Therapy

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand the mechanism of action of BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for patients with MM, and appreciate the similarities and differences among currently available and investigational agents in this class.
• Develop an understanding of the current clinical research database with FDA-approved BCMA-directed CAR T-cell therapy platforms in the management of relapsed/refractory MM in order to optimally integrate this novel therapeutic strategy into treatment algorithms.
• Appreciate the scientific justification for the development of next-generation BCMA-directed CAR T-cell approaches, and appraise available research findings with and ongoing efforts attempting to definitively establish the efficacy and safety of these agents.
• Review the biological rationale for and published research findings with CAR T-cell therapy targeting GPRC5D (G protein-coupled receptor class C group 5 member D) for MM, and evaluate the potential role of this therapeutic strategy.
• Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with CAR T-cell therapy for MM, and develop strategies to optimally identify and manage these side effects.
• Recognize the spectrum, frequency and severity of other adverse events, such as secondary hematologic cancer, infections and cytopenias, associated with CAR T-cell therapy used in the care of patients with MM, and consider recommended approaches to prevent, ameliorate and manage these toxicities.
• Recall available data with novel CAR T-cell therapy-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Larson — Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Kite, A Gilead Company, Pfizer Inc, Regeneron Pharmaceuticals Inc; Speakers Bureaus: Regeneron Pharmaceuticals Inc; Stock OPTIONS — Private Companies: TORL BioTherapeutics (founders’ shares). Dr Richard — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Legend Biotech; Consulting Agreements: Bristol Myers Squibb, Karyopharm Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, C4 Therapeutics, Heidelberg Pharma AG, Johnson & Johnson. Additional faculty to be announced.

MODERATOR
Dr Voorhees — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CellCentric, GSK, Johnson & Johnson, Kite, A Gilead Company, Legend Biotech, Predicta Biosciences, Regeneron Pharmaceuticals Inc; Consulting Agreements: Karyopharm Therapeutics; Contracted Research: AbbVie Inc, GSK, Johnson & Johnson, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationships: Multiple Myeloma Research Consortium. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Bristol Myers Squibb.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

Topics to Be Discussed

• Bispecific Antibody Therapy for Diffuse Large B-Cell Lymphoma
• Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes
• Novel Bispecific Antibodies Undergoing Evaluation for Non-Hodgkin Lymphoma
• Tolerability Considerations with CD20 x CD3 Bispecific Antibodies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma (NHL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among available agents in this class.
• Evaluate the available clinical research database with CD20 x CD3 bispecific antibodies in the management of diffuse large B-cell lymphoma (DLBCL), and optimally incorporate this approach into current treatment algorithms.
• Assess available research findings with CD20 x CD3 bispecific antibodies for follicular lymphoma (FL), and identify patients for whom this therapeutic modality should be considered and/or recommended.
• Evaluate published clinical research data with CD20 x CD3 bispecific antibodies in combination with other systemic therapies, and consider the current implications of these findings for DLBCL and FL management.
• Develop an understanding of the biological rationale for and current clinical research database with investigational CD19 x CD3 bispecific antibodies in the management of NHL, and reflect on the ongoing evaluation and potential role of these agents.
• Recognize adverse events associated with available and investigational bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing studies attempting to further define the optimal role of bispecific antibody-based strategies in therapy for NHL, and appropriately counsel patients regarding clinical trial participation.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bartlett — Advisory Committees: ADC Therapeutics; Contracted Research: AbbVie Inc, Allogene Therapeutics, Autolus, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Lilly, Seagen Inc, Takeda Pharmaceuticals USA Inc, Treeline Biosciences. Prof Cheah — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc. Additional faculty to be announced.

MODERATOR
Dr Patel — Advisory Committees (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck; Consulting Agreements (All Paid to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck, Pfizer Inc, Sanofi; Contracted Research (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Immunome, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Genmab US Inc.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 7:30 AM to 9:30 AM central time (8:30 AM to 10:30 AM eastern time).

Topics to Be Discussed

• Nontargeted Treatment for Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) 
• Role of FLT3 Inhibition in AML Management 
• IDH1/2-Targeted Therapy for AML 
• Current and Future Use of Menin Inhibitors for AML 
• Other Novel Agents and Strategies Under Investigation for AML  

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for individuals with primary and secondary AML to optimize clinical and quality of life outcomes. 
• Evaluate the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current role of this strategy. 
• Assess the scientific justification for and published research findings with oral hypomethylating agent therapy for AML to determine the current and appropriate clinical application of this therapeutic approach. 
• Reflect on available research evidence with approved FLT3 inhibitors, and use this information to guide the clinical management of newly diagnosed or progressive AML harboring a FLT3 mutation. 
• Understand available efficacy and safety data with IDH1 inhibitors for patients with IDH1 mutation-positive AML, and integrate this novel approach into current treatment algorithms. 
• Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the current and potential role of these novel agents. 
• Review the biological rationale for, published efficacy and safety data with and ongoing evaluation of CD123-targeted therapy for patients with AML, and consider the future role of these agents. 
• Understand the spectrum, incidence and severity of side effects associated with targeted therapies employed in AML management, and develop appropriate monitoring and management protocols. 
• Recall new data with novel agents and strategies currently under investigation for AML, and discuss ongoing trial opportunities with eligible patients. 

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — Prof de Botton has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr DiNardo — Advisory Committees: Astellas, Daiichi Sankyo Inc, Kura Oncology, Pfizer Inc, Syndax Pharmaceuticals, SystImmune Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Servier Pharmaceuticals LLC, Solu Therapeutics; Contracted Research: AbbVie Inc, Auron Therapeutics, Bristol Myers Squibb, PMV Pharmaceuticals, Remix Therapeutics, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC, SystImmune Inc; Data and Safety Monitoring Boards/Committees: Genmab US Inc. Dr Erba — Advisory Committees: Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Sumitomo Pharma America; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Pharma America, Taiho Oncology Inc; Contracted Research: Agios Pharmaceuticals Inc, ALX Oncology, Aptose Biosciences Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, ImmunoGen Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, Rigel Pharmaceuticals Inc, Sumitomo Pharma America, Taiho Oncology Inc; Speakers Bureaus: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals. Prof Wei — Advisory Committees: AbbVie Inc, Aculeus Therapeutics, Astellas, BeOne, Bristol Myers Squibb, Geron Corporation, Johnson & Johnson, Molecular Partners, Pfizer Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Consulting Agreements: Cycuria Therapeutics, Johnson & Johnson, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Dimericon Therapeutics, Johnson & Johnson, Mendus, PharmaEngine Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Financial Benefits via Institution: The Walter and Eliza Hall Institute (WEHI) receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei is an employee of WEHI and receives such a financial benefit; Speakers Bureaus: AbbVie Inc, Astellas.

MODERATOR
Dr Fathi — Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Azurity Pharmaceuticals, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Johnson & Johnson, Kura Oncology, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Thermo Fisher Scientific; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Kura Oncology, Servier Pharmaceuticals LLC.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Kura Oncology, Rigel Pharmaceuticals Inc, and Taiho Oncology Inc.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Wednesday, September 9^th from 11:56 AM to 12:56 PM central time (12:56 PM to 1:56 PM eastern time).

Educational Lunch Meeting

In-person attendees, please check in 15 minutes before the start of the meeting.

Module 1: Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) 

• Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies for MM 

• Available efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab and the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated MM; optimal incorporation into current management algorithms 

• Published findings from the Phase III MajesTEC-3 trial supporting the recent FDA approval of teclistamab in combination with subcutaneous daratumumab for patients with R/R MM after ≥1 prior line of treatment 

• Positive findings from published (MajesTEC-9) and emerging (MagnetisMM-5) Phase III studies evaluating BCMA-targeted bispecific antibodies as monotherapy in earlier lines of treatment 

• Recently presented results of the Phase III 
  MonumenTAL-3 trial of talquetamab combined with daratumumab with and without pomalidomide for R/R MM after ≥1 prior line of therapy; potential role of this approach 

• Emerging positive findings from and implications of the Phase III MonumenTAL-6 trial of talquetamab in combination with teclistamab or pomalidomide after 1 to 4 prior lines of therapy 

• Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab for R/R MM; ongoing Phase III CEVOLUTION trial combining cevostamab with pomalidomide and dexamethasone 

MODULE 2: Utility of Antibody-Drug Conjugates for R/R MM 

• Mechanism of action and structural components of belantamab mafodotin 

• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM 

• Extended efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7 

• FDA approval and current role of belantamab mafodotin/bortezomib/dexamethasone in the management of R/R MM 

• Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events, including ocular toxicities 

• Ongoing studies attempting to further elucidate the role of belantamab mafodotin for MM 

MODULE 3: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) and Other Promising Novel Agents and Strategies for R/R MM 

• Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs 

• Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM 

• Recently presented data from the Phase III SUCCESSOR-2 trial assessing mezigdomide/carfilzomib/dexamethasone versus carfilzomib/dexamethasone for R/R MM 

• Ongoing FDA review of new drug applications for iberdomide in combination with daratumumab/dexamethasone and mezigdomide in combination with carfilzomib/dexamethasone for patients with R/R MM, the former with priority review status; potential role of these regimens 

• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role 

• Rationale for the evaluation of chimeric antigen receptor (CAR) T-cell platforms with novel targets or manufacturing processes for R/R MM 

• Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA Regenerative Medicine Advanced Therapy Designation and ongoing evaluation in the QUINTESSENTIAL and QUINTESSENTIAL-2 studies 

• Other promising novel strategies in clinical development for patients with R/R MM 

Target Audience
This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists and other healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors affecting the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). 
• Assess available and emerging research data with B-cell maturation antigen (BCMA)-directed and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms.
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM. 
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators (CELMoDs) in order to identify patients with R/R MM who are optimal candidates for CELMoD-containing regimens.  
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM. 
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients. 

CE Credit
CME credit information will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma, Takeda Pharmaceutical Company Limited. Dr Raje — Advisory Boards and Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Caribou Biosciences Inc, GSK, Immuneel Therapeutics, Johnson & Johnson, Kelonia Therapeutics, Pfizer Inc, Sanofi; Contracted Research: Pfizer Inc; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb.

MODERATOR
Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Sanofi.

EDITOR
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.

George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Phone: (713) 853-8000

Meeting Room
Level 3 in Grand Ballroom B (Theater Room 2)

Map

This event has passed.

Thank you for your interest in our CME program. Online registration for the in-person event is now closed. SEATS ARE STILL AVAILABLE FOR THE SESSION. The onsite registration desk will open 15 minutes prior to the session start time. If you are interested in attending, please visit the registration desk outside Grand Ballroom B, Theater Room 2 at the George R Brown Convention Center, where the SOHO 2026 Annual Meeting is taking place. 

Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. 

NOTICE: 
Registration for this event is separate from registration for the SOHO 2026 Annual Meeting. Attendees must be registered for the SOHO Annual Meeting to participate in satellite symposia.

Join us on Saturday, August 22^nd from 9:00 AM to 2:20 PM central time (10:00 AM to 3:20 PM eastern time). Breakfast and lunch buffets sponsored by AON.

• 9:00 AM – 9:05 AM — Introduction (Dr Divers)
• 9:05 AM – 9:55 AM — Module 1: Chronic Lymphocytic Leukemia (Dr Awan)
• 9:55 AM – 10:45 AM — Module 2: Gastroesophageal Cancers (Dr Klempner)
• 10:45 AM – 11:00 AM — Morning Break
• 11:00 AM – 11:50 AM — Module 3: Ovarian and Endometrial Cancer (Dr Westin)
• 11:50 AM – 12:40 PM — Lunch
• 12:40 PM – 1:30 PM — Module 4: Diffuse Large B-Cell Lymphoma (Dr LaCasce)
• 1:30 PM – 2:20 PM — Module 5: Lung Cancer (Dr Liu)
• 2:20 PM — Meeting adjourns

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Chronic Lymphocytic Leukemia (CLL)
Upon completion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients newly diagnosed with this disease. 
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences. 
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents. 
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options. 
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line therapy for CLL to effectively inform patients about the risks and benefits of this novel treatment strategy.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with this strategy for patients with newly diagnosed and relapsed/refractory (R/R) CLL. 
• Appraise clinical investigator best practices for various R/R CLL management scenarios, and leverage this information to facilitate improved therapeutic decision-making. 
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients. 

Gastroesophageal Cancers
Upon completion of this activity, participants should be able to 

• Review published research findings with HER2-targeted therapies for patients with newly diagnosed and R/R advanced HER2-positive gastroesophageal cancers, and assess the current role of various agents and regimens. 
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms. 
• Evaluate the biological rationale for the use of claudin 18.2 (CLDN18.2)-directed monoclonal antibody therapy in combination with chemotherapy as first-line treatment for HER2-negative, CLDN18.2-positive gastric or GEJ cancer, and optimally deploy this approach in patient care. 
• Recognize available clinical research findings with immune checkpoint inhibitors as neoadjuvant, adjuvant or perioperative therapy for patients with resectable gastric, GEJ and esophageal cancers, and consider the current role of these approaches. 
• Review the rationale for, available data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers in order to prepare for potential clinical availability or to enhance clinical trial participation. 

Ovarian and Endometrial Cancer
Upon completion of this activity, participants should be able to 

• Recognize the rationale for targeting folate receptor alpha (FRα) in ovarian cancer (OC), and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs). 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the role of this novel therapeutic strategy. 
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and integrate this novel approach into current management algorithms. 
• Assess the incidence of cadherin-6 expression in OC, and understand available data with and the structural components and mechanism of action of novel ADCs directed at this target. 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease. 
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing gynecologic cancers, and consider the role of various approaches in patient care. 
• Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed ADCs for patients with gynecologic cancers, and consider available and emerging research findings with and the clinical potential of these agents. 
• Describe the scientific justification for, published data with and current research studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients. 

Diffuse Large B-Cell Lymphoma (DLBCL)
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate. 
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and R/R DLBCL, and consider the current and future role of this therapeutic strategy. 
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted ADCs for R/R DLBCL. 
• Evaluate available clinical trial findings and ongoing research studies with BTK inhibitors for DLBCL. 
• Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with DLBCL. 
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for various forms of DLBCL, and assess the similarities and differences among currently available agents in this class. 
• Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for the management of R/R DLBCL, and optimally incorporate these approaches into current treatment algorithms. 
• Assess available research findings with CD19-directed bispecific antibodies for DLBCL, and consider the potential role of these agents in therapy for patients with this disease. 
• Recall new data with agents and strategies currently under investigation for DLBCL, and discuss ongoing trial opportunities with eligible patients. 

Lung Cancer
Upon completion of this activity, participants should be able to

• Appreciate the incidence of HER2 mutations and overexpression in metastatic non-small cell lung cancer (NSCLC), and recognize published clinical trial data with and the current role of novel ADCs for HER2-positive disease. 
• Review available clinical trial data evaluating the efficacy and safety of HER2-targeted tyrosine kinase inhibitors for patients with HER2-mutant NSCLC, and optimally identify individuals appropriate for this novel therapeutic strategy. 
• Convey the clinical relevance of a positive ROS1 mutation testing result to appropriate patients with NSCLC, and appreciate available clinical research findings with recently approved and emerging agents demonstrating efficacy for these individuals. 
• Appreciate the biological rationale for the evaluation of TROP2-directed ADCs for various lung cancer patient populations, and identify individuals appropriate for therapy with FDA-approved and investigational agents. 
• Understand the biology of EGFR exon 20 insertion mutations, and evaluate how currently available and emerging therapies can be employed in the care of patients with NSCLC harboring these abnormalities. 
• Reflect on investigational agents and strategies currently in testing for lung cancer in preparation for the potential clinical availability of these approaches. 

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 4.25 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statement
This educational activity for 4.25 contact hours is provided by Research To Practice.

This activity is awarded 4.25 ANCC pharmacotherapeutic contact hours.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/AON2026/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.0425 CEU (4.25 contact hours) of continuing education credit. To receive 4.25 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc. Dr Klempner — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock OPTIONS — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation. Dr LaCasce — Advisory Committees: Caribou Biosciences Inc, Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Genmab US Inc, Pierre Fabre, Takeda Pharmaceuticals USA Inc. Dr Liu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Avenzo Therapeutics, BioNTech SE, Cogent Biosciences, Duality Biologics, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Henlius, MediLink Therapeutics, Merck, Merus, Nuvalent, Nuvation Bio Inc, OSE Immunotherapeutics, Puma Biotechnology Inc, Synthekine, SystImmune Inc. Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

MODERATOR
Dr Divers — Advisory Committees: Daiichi Sankyo Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP,  BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Genmab US Inc, Jazz Pharmaceuticals Inc, and Lilly.

JW Marriott Nashville
201 8th Avenue South
Nashville, TN 37203
Hotel Phone: (615) 291-8600

Meeting Room
Griffin A, B, C, D (second floor)

Hotel Room Reservations

• American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
• For all other registrants, room reservation information will be included in the confirmation email after you have registered for this program.

MODULES 1, 2 AND 3: Chronic Lymphocytic Leukemia, Gastroesophageal Cancers and Ovarian and Endometrial Cancers

• Slide Presentations (PDF)
• Slide Presentations (PPT)

MODULES 4 AND 5: Diffuse Large B-Cell Lymphoma and Lung Cancer

• Slide Presentations (PDF)
• Slide Presentations (PPT)

This event has passed.

Thank you for your interest in our CME/MOC, ACPE and NCPD program. At this time online registration for in-person attendance is closed for this event. 

Our onsite registration desk will be open at 8:30 AM central time on Saturday, August 22nd. If you are interested in attending, please visit our registration desk in the foyer of Griffin Ballroom A-D on the second floor of the JW Marriott Nashville hotel. Please note, seating is limited for this event, and we will do our best to accommodate onsite registrants on a first come, first served basis but prioritizing clinicians in practice. Onsite registration does not guarantee participation in meal services.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.